Checkpoint Therapeutics Inc’s Post

Lots of antibody-related data will be presented at AACR! Navrogen, Inc. will present preclinical data on its next-generation anti-CD20 antibody, NAV-006, and ICAM-1 refractory antibody-drug conjugate platform at the 2024 American Association for Cancer Research (AACR) Conference in San Diego, California, April 8-9. Navrogen is conducting IND-enabling studies with NAV-006, which was generated using the company's Block-Removed Immunoglobulin Technology (BRITE). The BRITE enhancement removes the HIO-1 (CA125) binding site so that NAV-006 is more effective than rituximab at killing lymphoma cells. NAV-006 is being developed for treating HIO-1-positive non-Hodgkin’s lymphoma. #mabs https://lnkd.in/euasJ9yJ

#transcript Joe Ferra CEO of Elevation Oncology highlights the unmet needs in gastric cancer & the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates ADCs confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer & esophageal cancer. ElevationOncology.com https://lnkd.in/dpGYCKGK

IN8bio presents data showing INB-300 demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. “INB-300 can selectively target leukemia cells while preserving healthy tissue. We are now conducting further optimization to improve the integration of membrane-bound IL-15 co-expression to potentially enhance both the efficacy and safety of next-generation adoptive cell therapies against a wider spectrum of cancers,” said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.” #AACR24 Read the release: https://lnkd.in/ez7dy7jC

As of the end of 2023, 14 BsAbs have received approval, predominantly for cancer treatment, demonstrating their potential in addressing various malignancies through different mechanisms, such as dual signaling pathway modulation, targeted receptor activation, and immune cell engagement. These antibodies come in various formats and target a broad spectrum of antigens, reflecting their versatility and potential for personalized cancer therapy. The development of bsAbs is guided by the biology of cancer, requiring careful selection of targets, epitopes, and antibody formats to optimize their efficacy and safety. #cancer #oncology #antibody https://lnkd.in/dJEk_RNC

“The chemokine receptor CCR8 is a promising target in cancer immunotherapy. Tumor-associated Tregs express CCR8, which is involved in the induction, expansion, migration, and immunosuppression of Tregs, making targeted inhibition of CCR8 signaling a potential therapeutic strategy against cancer.” “Here, authors generated mAb1, an antagonist antibody against CCR8 and determined structures of CCR8 in complex with mAb1 or the agonist CCL1, providing insights into CCR8 inhibition and activation.” https://lnkd.in/dp55ZrEN

Is a tidal wave of TIL therapies in sight? 🔭 The recent approval of Iovance Biotherapeutics, Inc.’ TIL therapy has made it possible to treat the hundreds of thousands of people affected by skin cancer in the U.S. 👍 As this is the first non-CAR-T adoptive cell therapy to hit the market, companies like CTMC / A joint venture between Resilience + MD Anderson Cancer Center, Obsidian Therapeutics, KSQ Therapeutics, Inc., Turnstone Biologics, and Instil Bio are all developing TILs to treat solid tumors. 🏥 But how does the therapy work? How does it compare with CAR-T? What are its side effects? We spoke to Chantale Bernatchez about TILs and the impact of this FDA win on patients with melanoma and the cancer research community. 🎗️ Read our latest article to find out! 👇 https://lnkd.in/dBK_93v8 #TILtherapy #adoptivecelltherapy #cancertreatment #immunotherapy #skincancer #medicalinnovation #FDAApproval #cancerresearch #immunology #patientcare 

Elicio Therapeutics has announced a Trial in Progress poster presentation on the Phase 1/2 study design of ELI-002 7P, an investigational therapeutic cancer vaccine. The study aims to evaluate the safety and efficacy of ELI-002 7P as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma. The vaccine has shown promising results in reducing tumor biomarkers and eliciting strong T cell responses, which correlated with a reduced risk of relapse and death. The study builds on positive preliminary data from the 2-peptide formulation of ELI-002.

Boehringer Ingelheim invests in a different take on cell therapy - prokaryotic cell therapy :) With market crowded with - admittedly very exciting - cell therapy modalities and approaches, perhaps going after bacteria-based therapeutics is indeed the path towards true differentiation. "T3P-Y058-739 was developed using T3’s protein delivery platform that repurposes the bacterial type III secretion (T3S) system so that live bacteria can be harnessed to deliver immune-modulating proteins to cancer cells and tumor micro-environments while avoiding healthy tissue. The bacteria can carry several immune-modulatory proteins, allowing for immuno-oncology combination therapies to be delivered in a single agent. " https://lnkd.in/ebNFMyMV

With their targeted ability to bind to cancer cells directly using a cytotoxic “payload,” antibody-drug conjugates (ADCs) have emerged as promising precision therapies in the development of cancer treatments. Pfizer’s next-generation ADC technology platform is aimed at both well-established and novel targets, trailblazing the future of specialized cancer care. Check out this article in Nature to learn more. #Pfizer #cancerresearch #ADCtechnology #precisionmedicine #specializedcancercare

Introduction: BioNTech is at the forefront of developing next-generation monoclonal antibodies for oncology, with a robust pipeline targeting various solid tumors. Their latest presentations at the 2023 SITC Annual Meeting highlighted significant advancements in this field. Highlighted Programs: 1. BNT316/ONC-392 (Gotistobart): This anti-CTLA-4 antibody shows promise in patients with PD-(L)1 resistant metastatic non-small cell lung cancer (NSCLC), demonstrating safety and efficacy in early trials. 2. BNT116: An mRNA vaccine targeting advanced NSCLC. 3. BNT221: A T cell therapy for advanced melanoma. 4. BNT312 and BNT313: Innovative antibody therapies enhancing T-cell function and anti-tumor activity. Future Directions: BioNTech aims to advance these candidates through clinical trials, which potentially impact cancer treatment paradigms significantly. Their ongoing research emphasizes the synergistic potential of combining different immunotherapies to enhance patient outcomes. Opal Bio Pharma (OBP)